JP7881616B2 - キノリンアミン系化合物、その調製方法及びその医薬的応用 - Google Patents

キノリンアミン系化合物、その調製方法及びその医薬的応用

Info

Publication number
JP7881616B2
JP7881616B2 JP2023572661A JP2023572661A JP7881616B2 JP 7881616 B2 JP7881616 B2 JP 7881616B2 JP 2023572661 A JP2023572661 A JP 2023572661A JP 2023572661 A JP2023572661 A JP 2023572661A JP 7881616 B2 JP7881616 B2 JP 7881616B2
Authority
JP
Japan
Prior art keywords
general formula
group
groups
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023572661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519993A5 (cg-RX-API-DMAC7.html
JP2024519993A (ja
Inventor
方▲龍▼ ▲楊▼
▲敏▼▲強▼ ▲賈▼
▲煥▼宇 ▲湯▼
永雷 ▲闕▼
峰 ▲賀▼
▲維▼康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024519993A publication Critical patent/JP2024519993A/ja
Publication of JP2024519993A5 publication Critical patent/JP2024519993A5/ja
Application granted granted Critical
Publication of JP7881616B2 publication Critical patent/JP7881616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023572661A 2021-05-27 2022-05-27 キノリンアミン系化合物、その調製方法及びその医薬的応用 Active JP7881616B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110606803 2021-05-27
CN202110606803.1 2021-05-27
CN202110976020.2 2021-08-24
CN202110976020 2021-08-24
PCT/CN2022/095441 WO2022247920A1 (zh) 2021-05-27 2022-05-27 喹啉胺类化合物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2024519993A JP2024519993A (ja) 2024-05-21
JP2024519993A5 JP2024519993A5 (cg-RX-API-DMAC7.html) 2025-05-16
JP7881616B2 true JP7881616B2 (ja) 2026-06-29

Family

ID=84228425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572661A Active JP7881616B2 (ja) 2021-05-27 2022-05-27 キノリンアミン系化合物、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US20240327388A1 (cg-RX-API-DMAC7.html)
EP (1) EP4349831B1 (cg-RX-API-DMAC7.html)
JP (1) JP7881616B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240014059A (cg-RX-API-DMAC7.html)
CN (1) CN117222639B (cg-RX-API-DMAC7.html)
AU (1) AU2022283404A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024741A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219657A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013972A (cg-RX-API-DMAC7.html)
TW (1) TW202313592A (cg-RX-API-DMAC7.html)
WO (1) WO2022247920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436295A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物的可藥用鹽、晶型及其製備方法
TW202436296A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物晶型及其製備方法
CN116854634B (zh) * 2023-06-27 2025-12-09 广东药科大学 一种选择性ces2抑制剂、其制备方法及其作为药物的用途
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating activity of microrna-124
WO2025201294A1 (zh) * 2024-03-26 2025-10-02 深圳信立泰药业股份有限公司 一种吲哚类化合物及其制备方法与miR上调应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011026251A (ja) 2009-07-27 2011-02-10 Kowa Co 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
JP2017522313A (ja) 2014-07-17 2017-08-10 アビバックス 炎症性疾患の処置のためのキノリン誘導体
JP2018507215A (ja) 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体
WO2020127843A1 (en) 2018-12-20 2020-06-25 Abivax Quinoline derivatives for use in the treatment of inflammation diseases
WO2021151062A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton Univeristy Heterocyclic compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5648599A (en) * 1998-09-11 2000-04-03 Kyorin Pharmaceutical Co. Ltd. Phosphonic ester derivatives and process for producing the same
CN102625804B (zh) 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
WO2012037351A1 (en) 2010-09-17 2012-03-22 Glaxosmithkline Llc Compounds
CN104109165A (zh) 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CA2916623C (en) 2013-07-05 2021-09-14 Abivax Bicyclic compounds useful for treating diseases caused by retroviruses
WO2017158201A1 (en) 2016-03-18 2017-09-21 Ratiopharm Gmbh Process for preparing quinolin-2-yl-phenylamine derivatives and their salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011026251A (ja) 2009-07-27 2011-02-10 Kowa Co 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
JP2017522313A (ja) 2014-07-17 2017-08-10 アビバックス 炎症性疾患の処置のためのキノリン誘導体
JP2018507215A (ja) 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体
WO2020127843A1 (en) 2018-12-20 2020-06-25 Abivax Quinoline derivatives for use in the treatment of inflammation diseases
WO2021151062A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton Univeristy Heterocyclic compounds and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pittala, V. et al,Synthesis and endothelin receptor binding affinity of a novel class of 2-substituted-4-aryl-3-quinolinecarboxylic acid derivatives,Medicinal Chemistry,2008年,Vol.4, No.2,p.129-137
REGISTRY[online],2001.06.10-2019.06.09, [Retrieved on 2026.01.14], Retrieved from:STN, CAS登録番号2326619-17-2、2202256-32-2、2200044-75-1、1349424-69-6、1177731-40-6、933027-01-1、896629-07-5、403695-19-2、340220-04-4

Also Published As

Publication number Publication date
KR20240014059A (ko) 2024-01-31
JP2024519993A (ja) 2024-05-21
WO2022247920A9 (zh) 2023-01-05
EP4349831A4 (en) 2024-09-04
CN117222639B (zh) 2026-07-10
TW202313592A (zh) 2023-04-01
MX2023013972A (es) 2023-12-11
BR112023024741A2 (pt) 2024-02-15
CN117222639A (zh) 2023-12-12
EP4349831A1 (en) 2024-04-10
WO2022247920A1 (zh) 2022-12-01
US20240327388A1 (en) 2024-10-03
AU2022283404A1 (en) 2023-11-30
EP4349831B1 (en) 2026-08-19
CA3219657A1 (en) 2022-12-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260617

R150 Certificate of patent or registration of utility model

Ref document number: 7881616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150